Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Abstract

IntroductionEvidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.MethodsPatients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.ResultsA total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).ConclusionsData from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.

Outcomes of rituximab therapy in refractory lupus: A meta-analysis

“…Seventy-six of these articles had to be further excluded, as these provided incomplete data or had irrelevant objectives and were unsuitable for meta-analysis. Remaining 31 articles were included for meta-analysis (10)(11)(12)(13)(14)(15)(16)(17)(18)(19). Flowchart of the studies evaluated is represented in Figure 1.…”

A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis

“…Furthermore, the FDA approved the use of rituximab under certain circumstances for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), rheumatoid arthritis, and granulomatosis with polyangiitis and microscopic polyangiitis (18). Although it is not approved for use in MS, it is quite often used off-label (19). …”

Modulation of Autoimmunity and Atherosclerosis – Common Targets and Promising Translational Approaches Against Disease –

“…133 B cell depletion by a chimeric anti-CD20 antibody (rituximab) has substantial clinical benefit in many autoimmune and chronic inflammatory diseases, including type I diabetes, 134 RA, and SLE. 135 Rituximab-mediated B cell depletion was recently shown to improve endothelial function for at least 12 weeks in RA patients, at the same time as improved RA clinical disease activity and most inflammatory markers. 136 Consistent with these findings, a smaller trial reported favorable effects of anti-CD20 therapy on endothelial function.…”